B. Riley Securities Maintains Neutral on Kulicke & Soffa Indus, Raises Price Target to $55
B. Riley Securities analyst Craig Ellis maintains Kulicke & Soffa Indus (NASDAQ:KLIC) with a Neutral and raises the price target from $45 to $55.
Kulicke & Soffa Analyst Sees No Meaningful Rebound In Near Term; Recommends Moving To The Sidelines
Needham analyst Charles Shi has reiterated a Hold rating on the shares of Kulicke & Soffa Industries Inc (NASDAQ:KLIC). With the company guiding…
DA Davidson Maintains Buy on Kulicke & Soffa Indus, Lowers Price Target to $55
DA Davidson analyst Thomas Diffely maintains Kulicke & Soffa Indus (NASDAQ:KLIC) with a Buy and lowers the price target from $70 to $55.
5 Value Stocks To Watch In The Technology Sector
Understanding Value Stocks
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
Gainers
Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday.
12 Information Technology Stocks Moving In Wednesday’s After-Market Session
Gainers
Remitly Global (NASDAQ:RELY) shares rose 13.0% to $11.88 during Wednesday's after-market session. The company's market cap stands at $1.9 billion. As per the press release, Q2 earnings came out today.
Recap: Kulicke & Soffa Indus Q3 Earnings
Kulicke & Soffa Indus (NASDAQ:KLIC) reported its Q3 earnings results on Wednesday, August 3, 2022 at 08:05 PM.
Here's what investors need to know about the announcement.
B. Riley Securities Maintains Neutral on Kulicke & Soffa Indus, Lowers Price Target to $50
B. Riley Securities analyst Craig Ellis maintains Kulicke & Soffa Indus (NASDAQ:KLIC) with a Neutral and lowers the price target from $59 to $50.
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
